Synthesis of the Potent, Selective, and Efficacious beta-Secretase (BACE1) Inhibitor NB-360.
Rueeger, H., Lueoend, R., Machauer, R., Veenstra, S.J., Holzer, P., Hurth, K., Voegtle, M., Frederiksen, M., Rondeau, J.M., Tintelnot-Blomley, M., Jacobson, L.H., Staufenbiel, M., Laue, G., Neumann, U.(2021) J Med Chem 64: 4677-4696
- PubMed: 33844524 
- DOI: https://doi.org/10.1021/acs.jmedchem.0c02143
- Primary Citation of Related Structures:  
7B1E, 7B1P, 7B1Q - PubMed Abstract: 
Starting from lead compound 4 , the 1,4-oxazine headgroup was optimized to improve potency and brain penetration. Focusing at the 6-position of the 5-amino-1,4-oxazine, the insertion of a Me and a CF 3 group delivered an excellent pharmacological profile with a p K a of 7.1 and a very low P-gp efflux ratio enabling high central nervous system (CNS) penetration and exposure. Various synthetic routes to access BACE1 inhibitors bearing a 5-amino-6-methyl-6-(trifluoromethyl)-1,4-oxazine headgroup were investigated. Subsequent optimization of the P3 fragment provided the highly potent N -(3-((3 R ,6 R )-5-amino-3,6-dimethyl-6-(trifluoromethyl)-3,6-dihydro-2 H -1,4-oxazin-3-yl)-4-fluorophenyl)-5-cyano-3-methylpicolinamide 54 ( NB-360 ), able to reduce significantly A β levels in mice, rats, and dogs in acute and chronic treatment regimens.